NCT02162771View on ClinicalTrials.gov

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 14, 2014

Primary Completion Date

January 12, 2016

Study Completion Date

December 29, 2018

Conditions
Lymphoma, Follicular
Interventions
BIOLOGICAL

Rituxan

BIOLOGICAL

CT-P10

DRUG

Cyclophosphamide

DRUG

Vincristine

DRUG

Prednisone

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT02162771 - To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan | Biotech Hunter | Biotech Hunter